Trade Mark Journal No.2026/034 21 August 2026

UK00004427697 7 August 2026 (5)

MELZONIX

Class 5: Pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy; Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity.

Regeneron Pharmaceuticals, Inc.

Representative: Appleyard Lees IP LLP